Mehdi Hassan^1,2, Safdar Ali³, Jin Young Kim^2,*, Muhammad Sanaullah⁴, Hani Alquhayz⁵, Khushbakht Safdar⁶

CMC-Computers, Materials & Continua, Vol.76, No.2, pp. 1643-1663, 2023, DOI:10.32604/cmc.2023.038578

Abstract Breast cancer resistance protein (BCRP) is an important resistance protein that significantly impacts anticancer drug discovery, treatment, and rehabilitation. Early identification of BCRP substrates is quite a challenging task. This study aims to predict early substrate structure, which can help to optimize anticancer drug development and clinical diagnosis. For this study, a novel intelligent approach-based methodology is developed by modifying the ResNet101 model using transfer learning (TL) for automatic deep feature (DF) extraction followed by classification with linear discriminant analysis algorithm (TLRNDF-LDA). This study utilized structural fingerprints, which are exploited by DF contrary to conventional More >

MARIA-LUISA VEISAGA^1,2, MARIAM AHUMADA², STACY SORIANO², LEONARDO ACUNA³, WEI ZHANG³, IVY LEUNG², ROBERT BARNUM², MANUEL A. BARBIERI^1,2,3,4,5,*

BIOCELL, Vol.47, No.8, pp. 1835-1852, 2023, DOI:10.32604/biocell.2023.029076

Abstract Backgorund: Fruits and seed extracts of Annona montana have significant cytotoxic potential in several cancer cells. This study evaluates the effect of A. montana leaves hexane extract on several signaling cascades and gene expression in metastatic breast cancer cells upon insulin-like growth factor-1 (IGF-1) stimulation. Methods: MTT assay was performed to determine the proliferation of cancer cells. Propidium iodide staining and flow cytometry analysis of Annexin V binding was utilized to measure the progression of the cell cycle and the induction of apoptosis. Protein expression and phosphorylation were determined by western blotting analysis to examine the underlying cellular mechanism… More >

EFFAT ALEMZADEH¹, LEILA ALLAHQOLI², HAMIDEH DEHGHAN³, AFROOZ MAZIDIMORADI⁴, ALIREZA GHASEMPOUR³, HAMID SALEHINIYA^5,*

Oncology Research, Vol.31, No.5, pp. 667-675, 2023, DOI:10.32604/or.2023.028406

Abstract Liquid biopsy, including both circulating tumor cells and circulating tumor DNA, is becoming more popular as a diagnostic tool in the clinical management of breast cancer. Elevated concentrations of these biomarkers during cancer treatment may be used as markers for cancer progression as well as to understand the mechanisms underlying metastasis and treatment resistance. Thus, these circulating markers serve as tools for cancer assessing and monitoring through a simple, non-invasive blood draw. However, despite several study results currently noting a potential clinical impact of ctDNA mutation tracking, the method is not used clinically in cancer More > Graphic Abstract

LETIAN JIN, HETING CHEN, QI RUAN, RUI LIU, YIFENG FAN, XIUFANG XU, DAJIANG WANG^*, JIAHUI LU^*

BIOCELL, Vol.47, No.7, pp. 1483-1498, 2023, DOI:10.32604/biocell.2023.028457

Abstract During the chemotherapy of tumors, the cytotoxic effect of drugs is vital to kill tumor cells, and the delivery of a chemotherapeutic agent is of great importance for optimal therapeutic effects. The high in vivo clearance rate and low delivery efficiency of conventional chemotherapeutic agents affect the therapeutic effect. In recent years, the responsive drug delivery nanosystem has received increasing concern owing to its excellent biocompatibility, stable delivery performance, and controlled drug release strategies. To lucidly explain the cytocidal and immunotherapeutic effects of such responsive nanosystems in breast cancer, this review discusses the various stimuli and More >

Tawfeeq Shawly¹, Ahmed A. Alsheikhy^2,*

CMC-Computers, Materials & Continua, Vol.76, No.1, pp. 731-751, 2023, DOI:10.32604/cmc.2023.039433

Abstract More than 500,000 patients are diagnosed with breast cancer annually. Authorities worldwide reported a death rate of 11.6% in 2018. Breast tumors are considered a fatal disease and primarily affect middle-aged women. Various approaches to identify and classify the disease using different technologies, such as deep learning and image segmentation, have been developed. Some of these methods reach 99% accuracy. However, boosting accuracy remains highly important as patients’ lives depend on early diagnosis and specified treatment plans. This paper presents a fully computerized method to detect and categorize tumor masses in the breast using two… More >

LAZAR S. POPOVIC^1,2,*, GORANA MATOVINA-BRKO¹, MAJA POPOVIC^1,2, KEVIN PUNIE³, ANA CVETANOVIC^4,5, MATTEO LAMBERTINI^6,7

Oncology Research, Vol.31, No.3, pp. 221-238, 2023, DOI:10.32604/or.2023.028525

Abstract Triple-negative breast cancer (TNBC) is a disease with often an aggressive course and a poor prognosis compared to other subtypes of breast cancer. TNBC accounts for approximately 10%–15% of all diagnosed breast cancer cases and represents a high unmet need in the field. Up to just a few years ago, chemotherapy was the only systemic treatment option for this subtype (1). To date, TNBC is considered a heterogeneous disease. One of the existing classifications is based on the analysis of mRNA expression in 587 TNBC cases, in which Lehman et al. proposed six subtypes of… More > Graphic Abstract

SHUIZHONG CEN^1,#, XIAOJIE PENG^2,#, JIANWEN DENG^3,#, HAIYUN JIN⁴, ZHINAN DENG⁵, XIAOHUA LIN³, DI ZHU³, MING JIN⁶, YANWEN ZHU³, PUSHENG ZHANG³, YUNFENG LUO³, HONGYAN HUANG^3,*

Oncology Research, Vol.31, No.3, pp. 375-388, 2023, DOI:10.32604/or.2023.028256

Abstract Triple-negative breast cancer (TNBC) is characterized by fast growth, high metastasis, high invasion, and a lack of therapeutic targets. Mitosis and metastasis of TNBC cells are two important biological behaviors in TNBC malignant progression. It is well known that the long noncoding RNA AFAP1-AS1 plays a crucial role in various tumors, but whether AFAP1-AS1 is involved in the mitosis of TNBC cells remains unknown. In this study, we investigated the functional mechanism of AFAP1-AS1 in targeting Polo-like Kinase 1 (PLK1) activation and participating in mitosis of TNBC cells. We detected the expression of AFAP1-AS1 in the TNBC… More > Graphic Abstract

FRANCISCO RAÚL BORZONE^1,*, MARÍA BELÉN GIORELLO¹, LEANDRO MARCELO MARTINEZ², MARÍA CECILIA SANMARTIN^1,3, LEONARDO FELDMAN⁴, FEDERICO DIMASE⁵, EMILIO BATAGELJ⁶, GUSTAVO YANNARELLI³, NORMA ALEJANDRA CHASSEING^1,*

Oncology Research, Vol.31, No.3, pp. 361-374, 2023, DOI:10.32604/or.2023.028104

Abstract Breast cancer is the predominant form of carcinoma among women worldwide, with 70% of advanced patients developing bone metastases, with a high mortality rate. In this sense, the bone marrow (BM) mesenchymal stem/stromal cells (MSCs) are critical for BM/bone homeostasis, and failures in their functionality, transform the BM into a pre-metastatic niche (PMN). We previously found that BM-MSCs from advanced breast cancer patients (BCPs, infiltrative ductal carcinoma, stage III-B) have an abnormal profile. This work aims to study some of the metabolic and molecular mechanisms underlying MSCs shift from a normal to an abnormal profile… More >

KAIMIN FAN, JUNWEI WENG^*

BIOCELL, Vol.47, No.6, pp. 1199-1211, 2023, DOI:10.32604/biocell.2023.028516

Abstract Immunotherapy targets the dysfunctional immune system to induce cancer cell killing by CD8-positive T cells. Immune checkpoint inhibitors (ICIs), specifically anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-CTLA4 antibodies, have revolutionized the management of many malignancies due to their significant role in generating a durable clinical response. However, clinical data suggest that response rates to ICI monotherapy are low due to the immunologically silent characteristics of breast cancer (BC). Chemotherapy, surgery, radiotherapy, and targeted therapy were recently reported to alter the tumor microenvironment and enhance the ICI response. Some clinical studies supported that ICIs, in combination with More >

Alia Alshehri, Duaa AlSaeed^*

Intelligent Automation & Soft Computing, Vol.37, No.1, pp. 939-970, 2023, DOI:10.32604/iasc.2023.037096

Abstract One of the most prevalent cancers in women is breast cancer. Early and accurate detection can decrease the mortality rate associated with breast cancer. Governments and health organizations emphasize the significance of early breast cancer screening since it is associated to a greater variety of available treatments and a higher chance of survival. Patients have the best chance of obtaining effective treatment when they are diagnosed early. The detection and diagnosis of breast cancer have involved using various image types and imaging modalities. Breast “infrared thermal” imaging is one of the imaging modalities., a screening… More >